Machines designed and prototyped by Setup Automação with PIPE-FAPESP’s support could come to market costing 25% less than currently available devices.
The technology uses ultraviolet-C, which can inactivate the novel coronavirus. Startup BioLambda was supported by FAPESP and partnered with the Albert Einstein Jewish-Brazilian Hospital in São Paulo.
By means of specific biomarkers, a diagnostic test developed by the Brazilian startup Onkos shows whether a lump in the gland is benign or malignant, reducing the risk of unnecessary surgery.
Extracorporeal membrane oxygenation (ECMO) can keep patients alive until the disease recedes.
Operating in the São José dos Campos Technology Park, Autaza’s RIC has an optical system for automotive paint quality inspection using computer vision and artificial intelligence.
With FAPESP’s support, Hytron has developed a containerized solution for hydrogen production via ethanol reforming that eliminates the need for shipping by tanker trucks. The equipment can supply the gas to factories and vehicle service stations.
Technology based on nanoparticles identifies IgG antibodies and costs only about a fifth of similar devices now on the market. It was developed by scientists at the University of São Paulo and Brazilian startup Biolinker.
With FAPESP’s support, PangeiaBiotech develops genetically modified varieties of sugarcane that are protected against attacking insects and glyphosate-tolerant.
Startup supported by FAPESP has developed equipment for biological control of pests that affect soybean and cotton production.
Based on a reaction between yeast and the novel coronavirus, the test will rapidly detect the presence of SARS-CoV-2 in saliva and will be available by mid-2021.
Manufacturing execution system (MES) technology enables firms to implement industry 4.0.
Technology to manage hospital flows is being tested by health units in metropolitan São Paulo.
Food engineers in Brazil and France developed gels based on modified starch for use as “ink” to make foods and novel materials by additive manufacturing.
In laboratory tests, the material eliminated 79.9% of SARS-CoV-2 particles in three minutes and 99.99% in up to 15 minutes.
The new center will have the mission of conducting fundamental and applied research seeking the discovery of new therapeutic targets for the treatment of cancer.
